Althea Jordan sits in her white recliner while her physical therapist, Danielle Heltzel, kneels on the floor in front of her ...

ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...

Foralumab is under clinical development by Tiziana Life Sciences and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS).

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

Microglia have been revealed to first help spread Alzheimer’s disease pathology across the brain and then activate to limit ...

Learn all the strategies and approaches when caring for dementia at home. There is support to help caregivers cope with the challenges they face along their caregiving journey ...

The daily medication, called hydromethylthionine mesylate (HMTM), was developed by British firm TauRX in Aberdeen ...

Researchers at New York-based Advanced Science Research Center of the CUNY Graduate Center (CUNY ASRC) have identified a crucial mechanism that connects cellular stress in the brain to the progression ...

Officials are assessing whether hydromethylthionine mesylate (HMTM) shows sufficient promise to be given the green light for ...

CUNY scientists made a key Alzheimer's disease breakthrough, identifying a vital mechanism in the brain’s immune cells that ...

Researchers from Arizona State University and Banner Alzheimer’s Institute have discovered a surprising link between a common ...